Business Daily Media

Men's Weekly

.

Zuellig Pharma and Institut AllergoSan sign 10-year regional partnership to bring leading probiotic brand OMNi-BiOTiC® to key markets in Asia

New agreement marks major milestone for Zuellig Pharma as it focuses on expanding its consumer healthcare segment, and for Institut AllergoSan as it expands its global presence

SINGAPORE - Media OutReach Newswire - 19 July 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan, a research and development company that specialises in products made from natural substances such as probiotic bacteria, plant extracts and minerals.

Anita Frauwallner, founder and CEO of Institut AllergoSan (left) and John Graham, Group CEO, Zuellig Pharma (right) at the partnership signing ceremony to bring OMNi-BiOTiC® to key markets in Asia.
Anita Frauwallner, founder and CEO of Institut AllergoSan (left) and John Graham, Group CEO, Zuellig Pharma (right) at the partnership signing ceremony to bring OMNi-BiOTiC® to key markets in Asia.

Under this partnership, Zuellig Pharma will provide a wide spectrum of commercialisation support, including product registration, sales and marketing, and warehousing and distribution services to bring OMNi-BiOTiC®, one of Institut AllergoSan's leading probiotic brands, to key markets in Asia.

"Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years and this partnership represents a significant step forward in our commitment to delivering innovative and accessible healthcare solutions to patients in Asia. With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region. Together with Institut AllergoSan, we will leverage our combined expertise to enhance the well-being of consumers and drive forward our mission of making healthcare more accessible," said John Graham, Group CEO, Zuellig Pharma.

"We are dedicated to supporting consumers' pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results. OMNi-BiOTiC® is the top selling probiotic brand in all German-speaking markets in Europe such as Austria, Germany and Switzerland[1] and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life," adds Anita Frauwallner, founder and CEO of Institut AllergoSan.

Zuellig Pharma plans to launch OMNi-BiOTiC® in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets thereafter.


[1] IQVIA OTC Global Insights 2023, 03F1/A7F, IQVIA OTC Audits / Public Price in EUR.
Hashtag: #ZuelligPharma #InstitutAllergoSan #Healthcare #Probiotics #ConsumerHealthcare #GutHealth #Commercialisation



The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.

For more information, visit:

About Institut AllergoSan

Institut AllergoSan, based in Graz, Austria, was founded in 1991 by a group of integrative doctors and pharmacists together with Anita Frauwallner, who is now the managing director. Since then, the company has been focused on the scientific research and development of products made from natural substances such as probiotic bacteria, dietary fibres, micronutrients, and plant extracts. Through the intensive cooperation between Institut AllergoSan and recognised scientists from the fields of medicine, pharmacy, and biochemistry, it has been possible to build up a recognised research and competence centre focused on the largest organ of the human body - the intestine. This has resulted in the OMNi-BiOTiC®, OMNi-LOGiC® and META-CARE® product range, among others.

It has been a true pioneering spirit that drove Anita Frauwallner to embark on a largely unknown path more than 30 years ago: she has dedicated her life to microbiome research and the development of innovative, high-quality probiotics. This spirit has brought OMNi-BiOTiC® to rank today as number 3 on the global probiotic market and number 1 in German-speaking Europe and numerous other countries.

News from Asia

Tenchijin Named Finalist for IVS2025 LAUNCHPAD

Exhibiting at IVS Startup Market to Showcase Advanced Water DX Solutions TOKYO, JAPAN - Media OutReach Newswire - 30 June 2025 - Tenchijin Inc...

ESET and Canon Extends Regional Alliance to Combat Asia’s Security Challenges

SINGAPORE - Media OutReach Newswire - 30 June 2025 – ESET Asia Pte. Ltd. ("ESET"), a global leader in cybersecurity, and Canon Singapore Pte. Ltd. ("Canon") today announced the signing of a Memora...

Counterfeit and Refurbished Transducers Pose Serious Safety Risks

Merz Aesthetics® Hong Kong Launches Ultherapy® Authenticity Verification Reward Program This August Consumers Urged to Verify Ultherapy® Transducers Authenticity for Safe and Effective Treatments H...

Porsche Design Tower Bangkok and Curvistan Bangkok Host an Exclusive Preview of the "Electrifying Past. Present. Future." Exhibition

BANGKOK, THAILAND - Media OutReach Newswire - 28 April 2025 - Porsche Design Tower Bangkok showcased its commitment to innovation by hosting an exclusive evening reception with Curvistan Bangkok, ...

Hong Kong: Bridging Business Opportunities under the Belt and Road Initiative

HONG KONG SAR - Media OutReach Newswire - 30 June 2025 - As a global trade and financial centre and a key link in the Belt and Road Initiative (B&RI), Hong Kong plays a pivotal role in connect...

Octa Black: Octa broker's premium trading experience

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 1 July 2025 - Octa, a globally regulated and trusted broker since 2011, rewards its high-value clients in Indonesia, Malaysia, and Nigeria with a...

Gaw Capital Appoints Nicholas Toh as Managing Director – Head of Data Centre Platform, Asia (Ex-China)

SINGAPORE - Media OutReach Newswire – 1 July 2025 – Gaw Capital Partners, a leading multi-asset investment management firm, is pleased to announce the appointment of Mr. Nicholas Toh as Managin...

Prime Immigration Consultancy Announces Expansion of Service Offerings to Help Clients Achieve the Singapore Dream

SINGAPORE - Media OutReach Newswire - 1 July 2025 - Prime Immigration Consultancy (PIC), a Singapore-based immigration consultancy, has announced an expansion of its services to provide more comp...

ICONSIAM in Collaboration with Shanghai Yuyuan Tourist Mart Group Brings China’s Most Iconic Lantern Festival to Thailand for the First Time

“Yuyuan Lantern Festival 2025” Lights Up Bangkok to Celebrate 50 Years of Thai–Chinese Diplomatic Ties BANGKOK, THAILAND - Media OutReach Newswire - 1 July 2025 - ICONSIAM, the global landmark al...

SIBUR to expand cooperation with clients in Bangladesh

MOSCOW, RUSSIA - Media OutReach Newswire - 1 July 2025 - SIBUR, Russia's largest producer of polymers and synthetic rubbers, sees potential to increase supplies to Bangladesh following the launch ...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

pay.com.au appoints new CEO and Managing Director

The former COO will lead the company’s next growth phase, with ex-CEO Edward Alder transitioning into the role of Managing Director AUSTRALIA, 25...

Sell by LayBy